Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PeriNesta
- Development stage
- Phase 4
- Lead developer
- Gedeon Richter
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PeriNesta** was Mithra's investigational fixed-dose oral hormonal treatment for women in perimenopause who experienced hot flushes and other vasomotor symptoms while still requiring contraception. The proposed formulation comprised estetrol, a native fetal estrogen produced synthetically for pharmaceutical use, drospirenone, and an unspecified vitamin component. Estetrol provides estrogen-receptor agonism, while drospirenone provides progestogenic activity with antimineralocorticoid and antiandrogenic properties. Mithra discontinued the PeriNesta research program in 2021 before the planned safety study in women around 50 years of age was conducted.
- Other names
- PeriNesta
02
Targets
AR (Adrenergic receptors)MR (Mineralocorticoid receptor)PR (Progesterone receptor)ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on PeriNesta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PeriNesta.